Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537922 · ClinicalTrials.gov registry record
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
A clinical trial of Non-Small Cell Lung Cancer and Lung Cancer, Non-Small Cell, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
- Recruiting
- Registry status
- 2,200
- Enrollment target
- 4
- Study locations
NCT05537922: Recruiting study of Non-Small Cell Lung Cancer and Lung Cancer, Non-Small Cell, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
NCT05537922 is a study of Non-Small Cell Lung Cancer and Lung Cancer, Non-Small Cell that is actively recruiting participants, run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The registered enrollment target is 2,200 participants, above the 648-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (240% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05537922, a study of Non-Small Cell Lung Cancer and Lung Cancer, Non-Small Cell, is actively recruiting participants, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
- RECRUITING
- Registry status
- 2,200 participants
- Enrollment target
- 4
- Study locations
Study Summary
I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase. The retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs. The prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients. This cohort will be used to validate the results obtained from the retrospective model through the creation of a new model (P-Model), which will be used to create the final PDSS tool.
Primary Outcome
Prediction of response to immune checkpoint inhibitors in NSCLC
Conditions Studied
Study Locations (4)
Other
- Metropolitan Hospital - Athens
- Shaare Zedek Medical Center - Jerusalem
- Vall D'Hebron Institute of Oncology - Barcelona
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2027-10-01 |
What NCT05537922 shows while recruiting
NCT05537922 is an observational study that tracks outcomes without assigning an intervention. Its 2,200 participants enrollment target places it among the larger protocols in the corpus, above the 648-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (240% higher).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05537922 reports a single indexed study location in Other, Illinois.
Frequently Asked Questions
What is clinical trial NCT05537922 about?
NCT05537922 is a clinical study titled "I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy". I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of avail...
What is the current status of trial NCT05537922?
This trial is currently recruiting. The enrollment target is 2,200 participants. The study started on 2022-10-01. Estimated completion is 2027-10-01.
What conditions does trial NCT05537922 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell, Lung Adenocarcinoma, Lung Cancer Metastatic.
Who is sponsoring clinical trial NCT05537922?
This trial is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537922 being conducted?
This trial has 4 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05537922's enrollment target sits among peer trials
2,200 6th of 454 higher than 449 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI